Comments
Cadila Healthcare on Monday said patent litigation relating to Aptalis’ drug Canasa used for treatment of ulcerative colitis has been settled. As a result of the settlement, the company’s “US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Canasa in the United States beginning on June 13, 2019, or earlier under certain circumstances,” Cadila Healthcare said in a statement to the exchanges. Zydus Cadila had earlier received tentative approval from the United States Food and Drug Administration to market its generic version of Canasa (mesalamine suppository 1 gm), it added. Canasa is indicated to treat mildly to moderately active ulcerative colitis. The company’s product will be manufactured at the group’s topical plant at Ahmedabad, Cadila Healthcare said. Shares of Cadila Healthcare closed at ₹485.10 on the BSE, up 0.45 per cent from its previous day’s close.
Pincon Spirit on Monday informed the exchanges that it had entered into a tie-up with 26 retail outlets of Spencer’s Retail for sales and distribution of its edible oils Pincon Mustard Oil and Pincon Soya Oil. However, the announcement failed to lift the spirits for the stock, which resumed trading on Monday after the Securities Appellate Tribunal had stayed a SEBI order to the stock exchanges that led to the suspension of trading in the stock of Pincon Spirit. The stock plunged 20 per cent at ₹57.5 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.